贝伐单抗治疗转移性结肠癌导致的肠穿孔：发生率、病因及处理
Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
作者信息
Heinzerling John H, Huerta Sergio
机构信息
Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
出版信息
Curr Surg. 2006 Sep-Oct;63(5):334-7. doi: 10.1016/j.cursur.2006.06.002.
PMID:16971205
Abstract
Avastin (Bevacizumab) is a recently developed monoclonal antibody against vascular endothelial growth factor (VEGF) receptor that increases survival in patients with metastatic colorectal cancer. Bowel perforation is a known risk factor of unknown etiology associated with the use of Avastin. In this report, the incidence, risk factors, typical presentation, and management of patients with this complication is described.
摘要
阿瓦斯汀（贝伐单抗）是一种最近研发的针对血管内皮生长因子（VEGF）受体的单克隆抗体，可提高转移性结直肠癌患者的生存率。肠穿孔是与使用阿瓦斯汀相关的一种病因不明的已知风险因素。在本报告中，描述了该并发症患者的发病率、风险因素、典型表现及治疗方法。
Zotero 插件